From: Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution
 | 12-week model | |||
---|---|---|---|---|
eNOS+/+BD | eNOS-/-BD | eNOS+/+HFD | eNOS-/-HFD | |
Number of animals | 8 | 8 | 8 | 8 |
Body weight (g) | 28.1 ± 1.9 | 27.2 ± 2.4 | 42.8 ± 3.1* | 41.7 ± 2.4 |
Liver weight (g) | 1.2 ± 0.1 | 1.2 ± 0.2 | 2.3 ± 0.6* | 2.8 ± 0.5§ |
Visceral fat weight (g) | 0.6 ± 0.1 | 0.7 ± 0.3 | 2.0 ± 0.3* | 1.2 ± 0.3§ |
Liver weight/body weight ratio (%) | 4.2 ± 0.3 | 4.3 ± 0.6 | 5.2 ± 1.0* | 6.7 ± 1.0§ |
Visceral fat weight/body weight ratio (%) | 2.1 ± 0.4 | 2.4 ± 1.0 | 4.7 ± 1.0* | 3.0 ± 0.6§ |
Serum ALT (IU/L) | 9.2 ± 0.8 | 17.5 ± 9.3 | 74.8 ± 41.4* | 172.8 ± 58.2§ |
Fasting glucose (mg/dL) | 89.6 ± 8.0 | 85.7 ± 20.6 | 151.8 ± 36.4* | 135.8 ± 32.3 |
Fasting insulin (ng/mL) | 0.72 ± 0.41 | 0.57 ± 0.72 | 1.63 ± 0.81* | 2.10 ± 0.74 |
HOMA-IR | 2.9 ± 1.8 | 2.0 ± 2.5 | 11.0 ± 6.7* | 13.3 ± 6.6 |
Serum cholesterol (mg/dL) | 90.5 ± 3.8 | 85.1 ± 4.9 | 174.8 ± 22.9* | 263.0 ± 28.5§ |
Serum TG (mg/dL) | 24.8 ± 6.8 | 26.0 ± 5.6 | 31.3 ± 5.9* | 33.8 ± 8.2 |
Serum NEFA (mEq/L) | 1.2 ± 0.0 | 1.1 ± 0.2 | 1.8 ± 0.1* | 1.7 ± 0.3 |
Serum leptin (ng/mL) | 3.9 ± 2.0 | 3.5 ± 2.7 | 30.2 ± 4.4* | 31.6 ± 22.9 |